Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.
Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
Among the many struggles faced by the digital therapeutics industry is the difficulty of designing and running effective clinical trials of digital therapeutics.
Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis
UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and care technologies, raising $50 million.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year